check_circleStudy Completed

Contraception

Gravistat 125 Bioequivalenz

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
42
Trial Dates
April 2005 - September 2005
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Estradiol Valerate (EV, DS00124)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

Open-label, randomized, crossover study to investigate the bioequivalence of two different tablet formulations containing 0.050 mg ethinylestradiol and 0.125 mg levonorgestrel (with gelatin [SH D00342E] versus gelatin-free [SH D00342D]) and to compare the bioavailability of the gelatin-containing formulation to that of a microcrystalline suspension [SH M00342C] in healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A